Isis Pharmaceuticals, Alnylam Pharmaceuticals, Invitrogen and Zymed Laboratories, Becton Dickinson and Clontech, and Sangamo BioSciences | GenomeWeb

Isis to Lay Off 40 Percent Amid Reorganization

Isis Pharmaceuticals said this week that it is planning on laying off about 40 percent of its workforce as it reorganizes itself to focus on its most promising antisense-drug candidates.

According to Isis’ website, the company currently employs 450 people, meaning the layoffs would affect about 180 people.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.